IL1B and diabetes mellitus: Our study suggests that SGLT2 inhibitors offer not only improvements in metabolic profiles but also inhibition of IL-1β secretion and other pro-inflammatory cytokines, potentially reducing the development of CVD in high risk patients with diabetes.